



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

del

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/494,212 01/25/00 LIN

S USP9/68A-EI

Raymond Yat Chiu Chan
1050 Oakdale Ln
Arcadia CA 91006

HM22/0613

EXAMINER

SISSON, B	
ART UNIT	PAPER NUMBER

1655

DATE MAILED:

06/13/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No.

09/494,212

Applicant(s)

LIN ET AL.

Examiner

Bradley L. Sisson

Art Unit

1655

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 17 May 2001.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-3, 7-18, 20, 22, 23, 25, 26 and 29-35 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-3, 7-18, 20, 22, 23, 25, 26 and 29-35 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claims _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are objected to by the Examiner.
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- 15) ☐ Notice of References Cited (PTO-892)
- 16) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 17) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 10.
- 18) ☐ Interview Summary (PTO-413) Paper No(s). _____.
- 19) ☐ Notice of Informal Patent Application (PTO-152)
- 20) ☐ Other: _____.

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 17 May 2001 has been entered.

Specification

2. The amendment filed 17 May 2001 is objected to under 35 U.S.C. 132 because it introduces new matter into the disclosure. 35 U.S.C. 132 states that no amendment shall introduce new matter into the disclosure of the invention. The added material which is not supported by the original disclosure is as follows: The amended paragraphs as found at original page 6, line 12, bridging to page 7, line 2; page 8, lines 6-20; page 8, line 21, bridging to page 9, line 12; page 9, lines 13-27; and at page 10, lines 1-16.

Applicant is required to cancel the new matter in the reply to this Office Action.

3. The use of the trademark Nonidet P40 has been noted in this application. It should be capitalized wherever it appears and be accompanied by the generic terminology.

Although the use of trademarks is permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner that might adversely affect their validity as trademarks.

Claim Rejections - 35 USC § 112

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-3, 7-18, 20, 22, 23, 25, 26, and 29-35 rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized in *In re Wands*, 8 USPQ2d 1400 (CAFC 1988). They include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.

The Quantity of Experimentation Necessary

The amount of experimentation needed to practice the full scope of the claimed invention is on the order of several man years with little if any reasonable expectation of success.

Art Unit: 1655

The Amount of Direction or Guidance Provided and The Presence or Absence of Working

Examples

2/18 The specification provides only limited guidance. Specifically, the specification has been found to set forth ^ubut four examples that are set forth over two pages (pages 13-15):

Example 1, page 13, "Cell Fixation and Permeabilisation,"

Example 2, pages 13-14, "First Reverse Transcription and Polynucleotide Tailing of the First-Strand cDNAs;"

Example 3, page 14, "Denaturation, Double-Stranded cDNA Synthesis and Transcriptional Amplification;" and

Example 4, page 15, "Second Reverse Transcription, Denaturation, Double-Stranded cDNA Synthesis and mRNA Amplification."

Example 5, page 16, "Amplification Cycling Procedure."

The Nature of the Invention

The invention relates to the areas of chemistry and cellular physiology, areas that have been recognized by the court as being unpredictable and requiring of greater levels of disclosure. Further, the claimed invention relates directly to matters of physiology and chemistry, which are inherently unpredictable and as such, require greater levels of enablement. As noted in *In re Fisher* 166 USPQ 18 (CCPA, 1970):

In cases involving predictable factors, such as that, once imagined, other embodiments can be made without difficulty and their performance characteristics predicted by resort to

Art Unit: 1655

known scientific laws. In cases involving unpredictable factors, such as most chemical reactions and physiological activity, the scope of enablement obviously varies inversely with the degree of unpredictability of the factors involved.

The State of the Prior Art

The state of the prior art is one where the isolation of mRNA from specific cells and the generation of cDNA from said selected cells under highly controlled conditions had been developed to the point of effective reproducibility.

The Relative Skill of Those in the Art

The relative skill of those in the art most closely associated with the claimed invention is high, on par with those that hold a Ph.D. in biochemistry.

The Breadth of Scope of the Claims

The claims have sufficient breadth of scope so to encompass performing the various reactions under conditions that do not yield with any degree of certainty the desired amplification product. Further, the claims have sufficient breadth of scope so to encompass the practicing of the method under conditions where RNA is liable to be degraded.

The claimed method also relates to one performing hybridization reactions, e.g., the annealing between the primer and template as well as that which occurs between the complementary strands. As set forth in Carrico, (US Patent 5,200,313) the extent and specificity of hybridization is affected by the following principal conditions:

1. The purity of the nucleic acid preparation.

2. Base compositions of the probe - G-C base pairs will exhibit greater thermal stability than A-T or A-U base pairs. Thus, hybridizations involving higher G-C content will be stable at higher temperatures.

3. Length of homologous base sequences- Any short sequence of bases (e.g., less than 6 bases), has a high degree of probability of being present in many nucleic acids. Thus, little or no specificity can be attained in hybridizations involving such short sequences. From a practical standpoint, a homologous probe sequence will often be between 300 and 1000 nucleotides.

4. Ionic strength- The rate of reannealing increases as the ionic strength of the incubation solution increases. Thermal stability of hybrids also increases.

5. Incubation temperature- Optimal reannealing occurs at a temperature about 25 - 30 °C below the melting temperature for a given duplex. Incubation at temperatures significantly below the optimum allows less related base sequences to hybridize.

6. Nucleic acid concentration and incubation time- Normally, to drive the reaction towards hybridization, one of the hybridizable sample nucleic acid or probe nucleic acid will be present in excess, usually 100 fold excess or greater.

7. Denaturing reagents- The presence of hydrogen bond-disrupting agents, such as formaldehyde and urea, increases the stringency of hybridization.

8. Incubation- The longer the incubation time, the more complete will be the hybridization.

9. Volume exclusion agents- The presence of these agents, as exemplified by dextran and dextran sulfate, are thought to increase the effective concentrations of the hybridizing elements thereby increasing the rate of resulting hybridizations.

Art Unit: 1655

Further, subjecting the resultant hybridization product to repeated washes or rinses in heated solutions will remove non-hybridized probe. The use of solutions of decreasing ionic strength, and increasing temperature, e.g., 0.1X SSC for 30 minutes at 65 °C, will, with increasing effectiveness, remove non-fully complementary hybridization products.

While all of the above art-recognized hybridization parameters may not necessarily apply to the claimed amplification reaction, many of them do. The specification has not set forth in sufficient detail a reproducible method whereby the claimed method can be practiced without the skilled artisan first resolving such issues. The situation at hand is analogous to that in *Genentech v. Novo Nordisk A/S* 42 USPQ2d 1001. As set forth in the decision of the Court:

“ ‘[T]o be enabling, the specification of a patent must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation.’ *In re Wright* 999 F.2d 1557, 1561, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993); *see also Amgen Inc. v. Chugai Pharms. Co.*, 927 F. 2d 1200, 1212, 18 USPQ2d 1016, 1026 (Fed Cir. 1991); *In re Fisher*, 427 F. 2d 833, 166 USPQ 18, 24 (CCPA 1970) (‘[T]he scope of the claims must bear a reasonable correlation to the scope of enablement provided by the specification to persons of ordinary skill in the art.’).

“Patent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable. *See Brenner v. Manson*, 383 U.S. 519, 536, 148 USPQ 689, 696 (1966) (starting, in context of the utility requirement, that ‘a patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion.’) Tossing out the mere germ of an idea does not constitute enabling disclosure. While every aspect of a generic claim certainly need not have been carried out by an inventor, or exemplified in the specification, reasonable detail must be provided in order to enable members of the public to understand and carry out the invention. ‘It is true . . . that a specification need not disclose what is well known in the art. *See, e.g., Hybritech, Inc. v. Monoclonal Antibodies, Inc.*, 802 F.2d 1367, 1385, 231 USPQ 81, 94 (Fed. Cir. 1986). However, that general, oft-repeated statement is merely a rule of supplementation, not a substitute for a basic enabling disclosure. It means that the omission of minor details does not cause a specification to fail to meet the enablement requirement. However, when there is

Art Unit: 1655

no disclosure of any specific starting material or any of the conditions under which a process can be carried out, undue experimentation is required; there is a failure to meet the enablement requirement that cannot be rectified by asserting that all the disclosure related to the process is within the skill of the art. It is the specification, not the knowledge of one skill in the art, that must supply the novel aspects of an invention in order to constitute adequate enablement. This specification provides only a starting point, a direction for further research.

The aspect of the public being forced to resolve issues of conditions of operability and types and limitations of starting materials is considered to constitute undue experimentation.

Response to argument

5. Agreement is reached in that the cancellation of material added via the Amendment of 03 January 2001 has overcome the issue of new matter as set forth in the prior Office action. As noted above, however, the new amendment has also been found to introduce new matter into the specification.

6. At page 15 of the response of 17 May 2001, hereinafter the response, it is asserted that Examples 1 to 5 as found in the specification, and the publication of Lin et al., *Nucleic Acids Research* 27:4585-4589 (1999) enables the claimed invention.

The above argument has been fully considered and has not been found persuasive towards the withdrawal of the rejection for while the examples can certainly be relied upon for enabling purposes, such reliance on the disclosures of non-patent literature is not, especially if such reliance is for the disclosure of material that is essential to practicing the claimed invention.

7. At page 15, bridging to page 16 of the response it is asserted that the claims have been narrowed sufficiently so to overcome the issue of enablement and that the aspect of the claims encompassing unpredictable factors has been overcome. Argument is also advanced that the claimed method could be practiced in a matter of hours, not days.

8. The above argument has been fully considered and has not been found persuasive. Turning first to the scope issue, it is noted that the claimed method, using claim 1 as an example, encompasses performing the entire process within a cell. Upon review of Example 5 as found in the specification, it is apparent that at least a part of the experiment, if not the entire experiment, was conducted within a fixed cell. The claimed method encompasses performing the method both within and without a cell. The aspect of performing the experiment within a cell speaks to the issues of cellular physiology that *In re Fisher* has identified as being indicia of unpredictableness. Further, the method of claims 1, 2, 7-23, and 29-35 do not require any form of fixation so to safeguard the mRNA from degradation.

9. Applicant's argument that "the present invention is neither an in-vivo nor a chemical reaction." While one may argue the first aspect, the assertion that the claimed invention does not embody an chemical reaction is wholly rejected. Truly, the invention, if anything, is a method for performing a plurality of chemical reactions. While enzymes and buffers may be used, such does not render the claim method something other than a chemical reaction.

10. For the above reasons, and in the absence of convincing evidence to the contrary, the rejection is again applied against the claims.

Conclusion

11. This is a RCE of applicant's earlier Application No. 09/494,212. All claims are drawn to the same invention claimed in the earlier application and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the earlier application. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action in

this case. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no, however, event will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bradley L. Sisson whose telephone number is (703) 308-3978. The examiner can normally be reached on 6:30 a.m. to 5 p.m., Monday through Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Stephanie Zitomer can be reached on (703) 308-3985. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3592 for regular communications and (703) 308-0294 for After Final communications.

Application/Control Number: 09/494,212

Page 11

Art Unit: 1655

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

B. L. Sisson
Bradley L. Sisson
Primary Examiner
Art Unit 1655

BLS
June 11, 2001